Loading clinical trials...
Loading clinical trials...
Hypothesis: Valganciclovir prophylaxis can be discontinued before 3 months in CMV-seropositive renal transplant recipients receiving induction thymoglobulin when developing CMV-specific cellular immun...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Maimónides Biomedical Research Institute of Córdoba
NCT05325008 · BK Viremia, Kidney Transplant Infection, and more
NCT04542733 · Kidney Transplant Infection, BK Virus Infection
NCT05708534 · Kidney Transplant Infection
NCT05224583 · Polyomavirus Infections, BK Viremia, and more
NCT06825117 · Urinary Tract Infections, Kidney Transplant Rejection, and more
Hosìtal Universitario Reina Sofia
Córdoba
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions